These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 33450785)

  • 1. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
    Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
    Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade.
    Naidoo J; Page DB; Wolchok JD
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
    Moujaess E; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
    Khair DO; Bax HJ; Mele S; Crescioli S; Pellizzari G; Khiabany A; Nakamura M; Harris RJ; French E; Hoffmann RM; Williams IP; Cheung A; Thair B; Beales CT; Touizer E; Signell AW; Tasnova NL; Spicer JF; Josephs DH; Geh JL; MacKenzie Ross A; Healy C; Papa S; Lacy KE; Karagiannis SN
    Front Immunol; 2019; 10():453. PubMed ID: 30941125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
    Buchbinder EI; Desai A
    Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
    Friedman CF; Postow MA
    Curr Oncol Rep; 2016 Apr; 18(4):21. PubMed ID: 26922327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
    Warner AB; Postow MA
    Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.